VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

HOYA Corporation vs ChemoMetec A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

HOYA Corporation

7741 · Tokyo Stock Exchange

Market cap (USD)$60.3B
Gross margin (TTM)79.8%
Operating margin (TTM)29.6%
Net margin (TTM)27.3%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryJP
Data as of2025-12-28
Moat score
72/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into HOYA Corporation's moat claims, evidence, and risks.

View 7741 analysis

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Comparison highlights

  • Moat score gap: HOYA Corporation leads (72 / 100 vs 67 / 100 for ChemoMetec A/S).
  • Segment focus: HOYA Corporation has 5 segments (48.2% in Eye Health Domain (healthcare-related products)); ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing).
  • Moat breadth: HOYA Corporation has 7 moat types across 3 domains; ChemoMetec A/S has 4 across 2.

Primary market context

HOYA Corporation

Eye Health Domain (healthcare-related products)

Market

Ophthalmic products (eyeglass lenses, contact lens retail, intraocular lenses)

Geography

Global (eyeglass lenses & IOL); Japan (contact lens retail)

Customer

Optical retailers, consumers, hospitals/clinics

Role

Manufacturer and retailer

Revenue share

48.2%

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Side-by-side metrics

HOYA Corporation
ChemoMetec A/S
Ticker / Exchange
7741 - Tokyo Stock Exchange
CHEMM - Nasdaq Copenhagen A/S
Market cap (USD)
$60.3B
n/a
Gross margin (TTM)
79.8%
n/a
Operating margin (TTM)
29.6%
n/a
Net margin (TTM)
27.3%
n/a
Sector
Healthcare
Healthcare
Industry
Medical - Instruments & Supplies
n/a
HQ country
JP
DK
Primary segment
Eye Health Domain (healthcare-related products)
Life science research, cell and gene therapy, and bioprocessing
Market structure
Oligopoly
Oligopoly
Market share
n/a
15%-25% (estimated)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
72 / 100
67 / 100
Moat domains
Demand, Supply, Legal
Demand, Network
Last update
2025-12-28
2026-04-24

Moat coverage

Shared moat types

Brand TrustDesign In Qualification

HOYA Corporation strengths

Physical Network DensityCompliance AdvantageReputation ReviewsLearning Curve YieldNiche speech synthesis portfolio

ChemoMetec A/S strengths

Installed Base ConsumablesInteroperability Hub

Segment mix

HOYA Corporation segments

Full profile >

Eye Health Domain (healthcare-related products)

Oligopoly

48.2%

Med-Tech Domain (medical-related products)

Oligopoly

15.4%

Electronics-related products (semiconductor/display photomask materials, HDD substrates)

Oligopoly

30.6%

Imaging-related products (optical lenses and optical materials)

Competitive

5.3%

Other (speech synthesis software)

Competitive

0.5%

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.